Tissue Handling and Repository

组织处理和储存库核心（核心B）的目标是提供服务，以优化 收集和分析为研究项目、试点项目获得的匹配临床数据和生物标本 项目和临床组件。具体而言，核心将寻求提高临床数据的质量 收集，定义招募协议，通过共同的生物标本处理提高效率， 并建立一个共同的健康对照样本库，用于随后的功能研究。三 提出了具体目标。首先，我们建议加强临床数据收集。基于网络的临床数据 将为研究和临床试验开发、测试和分析收集工具。的 核心研究人员将与主要研究者合作制定方案， 在站点之间收集高质量的数据。预计对于每个项目，快速的开发时间和 将需要控制器，并且将累积适度规模的集合。第二，我们建议 制定并应用生物样本跟踪和中央样本处理的工作流程方法。 将开发工作流程方法，并将其应用于生物标本收集的划分、跟踪和链接 通过主要研究者、组织处理和储存库核心和辅助（例如病理学， 流式细胞术）实验室。外周血的血清、DMA和冷冻保存处理 将对1型糖尿病（T1DM）、原发性干燥综合征（Sjogren's syndrome） (pSS)、炎性肠病（IBD）和健康对照受试者。第三，我们建议发展一个 根据感兴趣的基因型分层的可重绘的健康对照和患者库。的增强 为了招募和召回适当的患者，建议使用共同的健康对照和数据集 使用外周血白细胞进行机制研究的性别、年龄和血统匹配对照。

The goal of the Tissue Handling and Repository Core (Core B) is to provide services to optimize the collection and analysis of matched clinical data and biospecimens obtained for the Research Projects, Pilot Project and Clinical Components. Specifically, the Core will seek to enhance quality of clinical data collections, define recruitment protocols, improve efficiencies through common biospecimens processing, and develop a common, healthy control sample pool for recall for subsequent functional studies. Three specific aims are proposed. First, we propose to enhance clinical data collections. Web-based clinical data collection instruments will be developed, tested and analyzed for Research Studies and Clinical Trials. The Core will work with Principal Investigators to develop protocols which will enhance uniform, complete and high quality data collection between sites. It is anticipated that for each project, rapid development time and investigator-control will be desired, and that modest-sized collections will be accrued. Second, we propose to develop and apply a workflow methodology for biospecimen tracking and central specimen processing. Workflow methodology will be developed and applied to divide, track and link biospecimens collections through the Principal Investigator, the Tissue Handling and Repository Core, and Ancillary (e.g. Pathology, Flow cytometry) Laboratories. Processing of serum, DMA, and cryopreservation of peripheral blood mononuclear cells will be performed for subjects with Type 1 diabetes (T1DM), primary Sjogren's syndrome (pSS), inflammatory bowel disease (IBD), and healthy control subjects. Third, we propose to develop a redrawable healthy control and patient repository stratified on genotypes of interest. Enhancement of a common healthy control and dataset is proposed for the purposes of recruiting and recalling appropriate gender, age and ancestry-matched controls for mechanistic studies using peripheral blood leukocytes.